Prospective Head-to-Head Comparison of 18 F-FDG and 68 Ga-FAPI PET/CT in De Novo and Recurrent Epstein-Barr Virus–associated Nasopharyngeal Carcinoma

Radiology Imaging Cancer 2026 Open access

Read full text
Authors: Bingxin Gu, Shuyi Lin, Liyan Bai, Chaosu Hu, Xiaomin Ou, Zhongyi Yang, Shaoli Song
DOI: 10.1148/rycan.250437
Cited by: 1
References: 33

Abstract

Gallium 68 fibroblast activation protein inhibitor PET/CT outperformed conventional methods (plasma Epstein-Barr virus DNA level, contrast-enhanced MRI/CT, and fluorine 18 fluorodeoxyglucose PET/CT) in nasopharyngeal carcinoma primary evaluation and recurrence monitoring, suggesting its potential clinical utility.

Fields of Study & Subjects

Peptidase Inhibition and Analysis Head and Neck Cancer Studies Viral-associated cancers and disorders

Publication details

Journal / source
Radiology Imaging Cancer
Publisher
Radiological Society of North America (RSNA)
Volume
8
Issue
2
Pages
e250437–e250437
Publication date
20 February 2026
Language
EN